Market Overview

ArQule Announces Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer at ASCO

ArQule, Inc. (NASDAQ: ARQL) today announced final data from a
randomized, placebo-controlled, double-blind, Phase 2 clinical trial
with tivantinib in combination with cetuximab and irinotecan in patients
with relapsed or refractory KRAS wild-type metastatic colorectal cancer
(CRC). These data were presented today at the 2013 Annual Meeting of the
American Society of Clinical Oncology (ASCO) (abstract number 3508) by
Dr. Cathy Eng, M.D., F.A.C.P., M.D. Anderson Cancer Center, Associate
Director, Colorectal Center.

“The multiple encouraging signals of clinical benefit observed in this
trial include consistent trends in improved progression free survival
(PFS), overall response rate (ORR) and overall survival (OS) in patients
who received tivantinib in combination with cetuximab and irinotecan,”

See full press release

Posted-In: News Guidance Contracts Management Global


Most Popular

Related Articles (ARQL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free